Ken Griffin Nymox Pharmaceutical Corp Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$0.19 - $0.49 $1,387 - $3,577
-7,300 Reduced 58.87%
5,100 $0
Q1 2023

May 15, 2023
SELL
$0.33 - $0.5 $1,122 - $1,700
-3,400 Reduced 21.52%
12,400 $4,000
Q4 2022

Feb 14, 2023
BUY
$0.28 - $0.74 $4,424 - $11,692
15,800 New
15,800 $5,000

Others Institutions Holding NYMX

# of Institutions
6
Shares Held
150K
Call Options Held
0
Put Options Held
0
View Full List

About NYMOX PHARMACEUTICAL CORP

NYMX Quotes by TradingView
  • Ticker NYMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,265,000
  • Market Cap $42.9M
  • Description
  • Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...
More about NYMX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email